Monoclonal Antibodies good option in pregnany due to neutralization?
Great…
If so use it for that….
Why the need to have so many people getting PEP?
Last updated August 30, 2021 at 9:32 a.m. EST
Various monoclonal antibody treatments are available only under emergency use authorization (EUA). They are recommended for the treatment of outpatients with mild to moderate COVID-19 infection who are at high risk of clinical progression as defined by the EUA criteria. Pregnancy is included among the conditions that put individuals at high risk for clinical progression. This makes patients with pregnancy as their only risk factor eligible to receive outpatient monoclonal antibodies, according to the EUA (NIH). Obstetric care clinicians may consider the use of monoclonal antibodies for the treatment of non-hospitalized COVID-19 positive pregnant individuals with mild to moderate symptoms, particularly if one or more additional risk factors are present (eg BMI >25, chronic kidney disease, diabetes mellitus, cardiovascular disease).
Post-exposure prophylaxis should be considered for inadequately vaccinated individuals who have been exposed to SARS-CoV-2 (NIH). These individuals include those who have had a recent exposure to an individual with SARS-CoV-2 for a cumulative total of 15 minutes or more over a 24-hour period or there is a recent occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting AND are 1) not fully vaccinated or 2) fully vaccinated but may not mount an adequate immune response.
The CDC currently recommends waiting 90 days to get the vaccine after receipt of monoclonal antibodies (CDC).
Efforts should be made to ensure that communities most affected by SARS-CoV-2 have equitable access to these treatments. Future data will likely inform optimal use of this therapeutic option by pregnant patients.